Whitbread to name Severn Trent's Hodgson as new chair
The chair of Severn Trent, the FTSE-100 water company, is to add to her portfolio of directorships by taking the helm of Whitbread, the Premier Inn-owner.
Sky News has learnt that Christine Hodgson has been selected as the preferred candidate to replace Adam Crozier as Whitbread's chairman.
City sources said her appointment could be announced as early as next week.
Money latest:
Ms Hodgson is said to have seen off competition for the post from Andrew Martin, chair of the testing and inspection group Intertek.
Mr Crozier, who has chaired the leisure group since 2018, is expected to step down later this year.
Ms Hodgson has some experience of the leisure industry, having served on the board of Ladbrokes Coral Group until 2017.
Under Mr Crozier's stewardship, Whitbread has been radically reshaped, selling its Costa Coffee subsidiary to The Coca-Cola Company in 2019 for nearly £4bn.
The company has also seen off an activist campaign spearheaded by Elliott Advisers, while Mr Crozier orchestrated the appointment of Dominic Paul, its chief executive, following Alison Brittain's retirement.
It said last year that it sees potential to grow the Premier Inn network from 86,000 UK bedrooms to 125,000 over the next decade or so.
The company has also been exploring the sale of some of its pub and restaurant operations.
On Thursday, shares in Whitbread were trading at around £28.41, giving the company a market capitalisation of about £4.8bn.
Whitbread declined to comment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt'), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow's Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences' CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women's health, respectively. Friedrich Kapp, M.D, Ph.D. is co-CEO of Adimune, Inc.('Adimune'), which is advancing its lead therapeutic candidate ADI-100™ towards an Investigational New Drug ('IND') submission to enable initiation of clinical trials with the antigen-specific gene therapy. ADI-100 is designed to restore immune tolerance in autoimmune diseases by targeting specific antigens, like glutamic acid decarboxylase, and establish tolerance in organ transplantation. Dr. Kapp, a 30+ year veteran of the pharmaceutical industry, was formerly president of the Therapeutics Business Unit at Schering AG. Chris Mitton was appointed president of Pearsanta, Inc. ('Pearsanta') in September 2024 to drive the advancement of its Mitomic ® diagnostic tests for endometriosis and prostate cancer. A seasoned veteran of the healthcare industry with over 20 years of leadership experience in the medical diagnostics sector and a strong focus on personalized healthcare and molecular oncology diagnostics, Mr. Mitton concurrently serves as CEO of MDNA Life Sciences Inc., a pioneer in the development of liquid biopsy tests. Saundra Pelletier is president, CEO and Chairman of the Board of Evofem Biosciences, Inc. (OTCPK: EVFM) ('EvoFem'). Her deep insight in women's health is driven by intensive consumer research and more than three decades of commercial experience in the global markets with products addressing women's health spanning every stage in their reproductive journey, from puberty to menopause. During her career, including her ten-year tenure at Evofem, she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. Ms. Pelletier is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women's healthcare. Pearsanta and Adimune are wholly-owned subsidiaries of Aditxt. About Aditxt, Inc. Aditxt, Inc. ('Aditxt') is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the planned acquisition of Evofem BioSciences, Inc. ('EvoFem')under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc. (jointly 'the Parties'), as amended (the 'A&R Merger Agreement'), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. For more information, please visit Follow Aditxt on: Aditxt™, Adimune™, ADI-100™, Pearsanta™, are trademarks and Mitomic ® is a registered trademarks of Aditxt, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," 'advancing', "aim," 'are working to,' "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt does not undertake any duty to update any forward-looking statement except as required by law.
Yahoo
4 hours ago
- Yahoo
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The first patient was enrolled at Yale School of Medicine's Department of Psychiatry, marking a significant milestone in the trial. The trial is evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to explore its potential in reducing alcohol cravings and consumption. This first-in-human study represents a pivotal step toward developing a groundbreaking treatment for individuals struggling with AUD. Eligible subjects for the clinical trial, among others, are individuals aged 18 to 60. Participants may be either non-treatment-seeking individuals who report heavy binge drinking (defined as at least five standard drinks in a day for men or at least four for women) on at least five days in the past month prior to screening, or treatment-seeking individuals diagnosed with Alcohol Use Disorder (AUD) per DSM-5 criteria, who report at least four binge drinking days in the month prior to screening. All subjects must express a desire to reduce or stop drinking. For more information: 'The enrollment of our first patient at Yale School of Medicine marks a pivotal milestone in the development of CMND-100,' said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. 'This advancement brings us one step closer to offering an innovative solution for those affected by AUD, a condition with significant unmet medical needs. The substance use disorder treatment market in the U.S. alone was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029. Moreover, there are hundreds of millions of individuals around the globe afflicted by AUD. However, the market has been constrained due to the limited effectiveness and adverse side effects of current treatment options. We are executing on our development strategy and are optimistic about the potential of our MEAI-based therapy to offer a safe, effective solution that can transform lives.' The Phase I/IIa clinical trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, while the Company is valuating additional clinical sites. Clearmind remains committed to advancing its robust intellectual property portfolio and pioneering psychedelic-derived therapeutics to address global health challenges. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relations invest@ Telephone: (604) 260-1566 US: CMND@ General Inquiries Info@ Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses conducting its Phase I/IIa clinical trial, developing a treatment for individuals struggling with AUD, the size of the substance use disorder treatment market, executing its development strategy, valuating additional clinical sites, and that it remains committed to advancing its robust intellectual property portfolio and pioneering psychedelic-derived therapeutics to address global health challenges. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Harry Kane-backed SeatUnique to score with £10m funding
A premium ticketing platform backed by the England football captain Harry Kane is raising a further £10m in funding to take advantage of the fast-growing 'experience economy'. Sky News has learnt that SeatUnique, which is run by co-founder Robin Sherry, is in talks to secure the new capital in an extension of its recent Series A round. The funding is expected to be committed entirely by existing investors, led by Nickleby Capital, which has backed a string of technology unicorns. Money latest: SeatUnique has deals with venues such as Wembley Stadium, Manchester's Co-op Live arena and the 16 racecourses operated by Arena Racing. A number of additional contracts are said to be under negotiation. Ben Stokes, the England men's Test cricket captain, and Dame Jessica Ennis-Hill, the 2012 Olympic heptathlon champion, are also backers of SeatUnique. One source close to the situation said the new funding was likely to be followed by a much larger Series B fundraising next year. The company is chaired by Richard Flint, the former SkyBet chief who also chairs the investment platform Hargreaves Lansdown. It markets original ticketing inventory, unlike secondary platforms which have come under growing political pressure for their treatment of consumers. SeatUnique declined to comment on its Series A extension.
